PATENT CLAIM ANALYSIS

Application Number: 16031418
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "141100"]

Abstract:
The present invention is directed to an anti-prion monoclonal antibody and its use for the treatment of conditions associated with or mediated by proteins or peptides having a toxic oligomeric form. These conditions include, but are not limited to, Alzheimer's disease, frontotemporal dementias, traumatic brain injury, and chronic traumatic encephalopathy.

Claim (Index 23):
A method of inhibiting onset of one or more symptoms of a condition mediated by a protein or peptide in an oligomeric toxic form a subject, said method comprising:\n administering to the subject the pharmaceutical composition of  claim 20 , wherein said composition is administered in an amount effective to prophylactically inhibit onset of one or more symptoms of the condition mediated by the protein or peptide in the oligomeric toxic form the subject.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 95.0
- Lexical Diversity: 1.20833
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13773264', '12999045', '14616300', '15324141', '14407724']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7038998926680783
- 35 USC 102 Novelty (BERT): 0.5379572928419857
- Combined Prediction Score: 0.687305632685469
- Mean Citation Score: 357.33605400000016
- Max Citation Score: 366.13882
- Similarity Product: 284.394104962312

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test